
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : KT110
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Assess the Pharmacokinetic Profile of Prazosin and Cyproheptadine
Details : KT110 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alcoholism.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 27, 2023
Lead Product(s) : KT110
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Cyproheptadine Hydrochloride,Prazosin Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : ECSOR
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : KT-110, a new and innovative approach based on dual receptor targeting. Study evaluates the efficacy, safety and tolerance of KT-110, a combination of 2 molecules protected by a compositional patent, on alcohol consumption in patients suffering from seve...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 30, 2021
Lead Product(s) : Cyproheptadine Hydrochloride,Prazosin Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : ECSOR
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Cyproheptadine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : ECSOR
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cyproheptadine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Alcoholism.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 27, 2019
Lead Product(s) : Cyproheptadine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : ECSOR
Deal Size : Inapplicable
Deal Type : Inapplicable
